{"id":"NCT00847808","sponsor":"Takeda","briefTitle":"Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy","officialTitle":"A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2009-02-19","resultsPosted":"2011-04-29","lastUpdate":"2012-02-03"},"enrollment":178,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"Dexlansoprazole MR QD","otherNames":["TAK-390","T-168390","TAK-390MR","Kapidex","Dexilant"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.","primaryOutcome":{"measure":"Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR.","timeFrame":"Week 3 through Week 6","effectByArm":[{"arm":"Dexlansoprazole MR QD","deltaMin":88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States"]},"refs":{"pmids":["22155561"],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=9efb34b3-fb69-4190-a2be-a90b8cb94e25&filetypecode=DEXILANTPI"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":178},"commonTop":["Diarrhoea","Headache","Cough","Flatulence","Upper respiratory tract infection"]}}